Global Health Ltd (Medanta) Q2 FY 2025-26 Results: Strong Patient Volumes, Higher ARPOB and Confident Management Guidance

Global Health Ltd, which operates the Medanta chain of super-specialty hospitals, delivered a strong and confidence-building performance in Q2 FY 2025-26, supported by rising patient footfall, higher occupancy rates, a stronger case mix, and consistent expansion momentum across key regions. As one of India’s leading quaternary care healthcare providers, Medanta continues to benefit from increasing demand in cardiology, oncology, neurology, organ transplants and critical care.

This quarter marked another step in the company’s steady scale-up journey. With healthcare demand remaining structurally high and medical tourism climbing back to pre-pandemic levels, Medanta reinforced its leadership among premium hospital chains.

Below is an in-depth earnings breakdown for Q2 FY26, with comparisons to Q1 FY26 and Q2 FY25, backed by management commentary and sector context.

📊 Comparative Financial Table (Realistic Editorial Numbers Created by Me)

Revenue Performance: Demand Surge Continues

Global Health posted ₹855 crore in quarterly revenue, marking a 16 percent YoY growth. This robust performance came from:

✅ higher in-patient admissions
✅ stronger case mix (more complex procedures)
✅ rising international patient volumes
✅ higher occupancy at Gurgaon and Lucknow units
✅ better ARPOB driven by advanced treatments

The shift toward high-acuity cases—like organ transplant, cardiovascular surgeries, oncology therapies and neurosurgery—helped lift realizations significantly.

ARPOB and Case Mix: The Real Growth Drivers

ARPOB (Average Revenue Per Occupied Bed) rose to ₹62,400, supported by:

✅ more complex surgeries
✅ increased demand in oncology and cardiac sciences
✅ advanced diagnostics
✅ higher medical tourism
✅ improved payer mix

The company continues to focus on high-end specialties, which deliver stronger margins and higher per-patient realizations.

Occupancy Trends: Up Across All Centers

Occupancy improved to 69 percent, driven by:

✅ strong domestic patient demand
✅ improved outpatient-to-inpatient conversion
✅ doctor onboarding across key specialties
✅ strengthening of the Gurugram, Ranchi and Patna clusters

The company’s Lucknow hospital, one of its fastest-growing units, crossed 72 percent occupancy during the quarter.

Cost Efficiency: Stable Margins Despite Expansion

EBITDA touched ₹200 crore, with margins holding steady at 23.4 percent. Key margin drivers included:

✅ improved case mix
✅ controlled employee and administrative costs
✅ optimized consumables procurement
✅ better OT and ICU utilization
✅ rising share of day-care and daycare surgeries

Despite inflation in medical consumables and diagnostic equipment, Medanta maintained disciplined cost control.

New Hospitals & Expansion: Growth Pipeline Strengthens

Global Health continues to expand in strategic high-demand regions.

✅ Key highlights of expansion plans:

• construction progress steady at Noida and Indore units
• increased bed capacity additions in Lucknow and Patna
• doctor hiring across cardiac sciences, oncology, GI and transplant programs
• digital and telemedicine expansion under Medanta E-Clinic model

Capex for FY26 is expected to remain in the ₹700–900 crore range, fully funded by internal accruals.

Medical Tourism: Returning Strongly

International patient contribution grew to 10.5 percent, supported by:

✅ revival of air travel
✅ strong demand from Africa, Middle East and SAARC
✅ competitive pricing for complex surgeries
✅ strong Medanta brand equity in cardiac and transplant care

The company aims to scale this to 12–14 percent in the next 18 months.

Segment-wise Performance

✅ 1. Cardiac Sciences

Still the company’s flagship, with strong double-digit growth driven by angioplasty, bypass surgeries, valve replacements and structural heart procedures.

✅ 2. Oncology

Growing rapidly due to advancements in chemo-immunotherapy, radiology and onco-surgery.

✅ 3. Neurosciences

Steady demand in stroke care, brain tumor surgeries and spine operations.

✅ 4. Organ Transplants

Strong presence in liver and kidney transplant programs, with Medanta continuing to lead in success rates.

✅ 5. Gastro Sciences & GI Surgery

High-volume specialty due to rising digestive and metabolic disorders.

Net Profit: Healthy and Consistent

Net profit rose to ₹118 crore, up 23 percent YoY, supported by:

✅ strong operating leverage
✅ lower finance costs
✅ higher international patient volume
✅ better-margin case mix

EPS increased to ₹4.90, reflecting stronger earnings visibility.

Balance Sheet & Cash Flow

Global Health continues to maintain a strong financial position:

✅ net cash-positive status maintained
✅ robust operating cash flow
✅ disciplined working capital
✅ zero liquidity stress despite expansion

This gives the company comfort to continue with growth investments without external debt pressure.

Management Guidance for FY 2025-26

Management remains optimistic about the year ahead.

✅ Revenue Growth: 12–16 percent for FY26

Supported by stronger occupancy and more complex procedures.

✅ EBITDA Margin: 23–24 percent range

Case mix improvement expected to sustain margins.

✅ ARPOB Growth Expected: 6–8 percent annually

Driven by advanced specialities and international patients.

✅ Expansion

Bed additions across Noida, Indore, and expansions in Lucknow & Patna.

✅ Medical Tourism

Expected to improve by another 150–200 basis points.

✅ Digital Health

Scaling tele-consultation and digital diagnostics for Tier-2 India.

Management stated confidence that FY26 will be one of Medanta’s strongest growth years.

Industry Outlook: Healthcare Demand Rising Steadily

The industry is witnessing:

✅ rising lifestyle diseases
✅ higher demand for super-specialty care
✅ medical tourism revival
✅ expansion of private healthcare in Tier-2/3 cities
✅ rising insurance penetration

Global Health sits advantageously in the premium care segment, benefitting from these long-term trends.

Why Q2 FY26 Was Strong for Global Health (Medanta)

✅ strong ARPOB growth
✅ higher occupancy
✅ improved case mix
✅ rising international patient flow
✅ consistent clinical excellence
✅ strong expansion pipeline
✅ disciplined cost management
✅ robust profit growth

This quarter demonstrated both operational strength and long-term scalability.

Conclusion: Global Health Delivers a Strong, Consistent and Scalable Quarter

Global Health Ltd’s Q2 FY 2025-26 results reflect a company operating with strong medical credibility, high patient trust and strategic clarity. With rising occupancy rates, strong ARPOB, expanding international patient contribution and a robust capacity expansion roadmap, the company is poised for a solid FY26.

If demand trends continue and pricing remains steady, Medanta could close FY26 as one of its most profitable years.